Clinical Trial Update: Safety and Efficacy of Recombinant Adeno-Associated Virus Containing the CFTR Gene in the Treatment of Cystic Fibrosis [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial evaluating a recombinant adeno-associated virus carrying the CFTR gene for cystic fibrosis was terminated after assessing safety and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Recombinant Adeno-Associated Virus Containing the CFTR Gene

Snippet

Sponsor: Targeted Genetics Corporation | Conditions: Cystic Fibrosis | Phase 2, Phase 3 | Status: TERMINATED